According to the Complaint, Synthorx, Inc. is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders.

This action stems from a proposed transaction announced on December 9, 2019, pursuant to which Synthorx will be acquired by Sanofi.

On December 7, 2019, Synthorx’s Board of Directors caused Synthorx to enter into an agreement and plan of merger with Sanofi.

On December 23, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on January 22, 2020.